Literature DB >> 7686841

Role of vasoactive intestinal peptide (VIP) in pathogenesis of ethanol-induced gastric mucosal damage in rats.

F Karmeli1, R Eliakim, E Okon, D Rachmilewitz.   

Abstract

To elucidate the possible role of vasoactive intestinal peptide (VIP) in the pathogenesis of acute gastric mucosal damage, rats were treated intragastrically with 1.0 ml 96% ethanol with or without intravenous or intraperitoneal coadministration of VIP (1 nmol/liter to 1 mumol/liter/100 g). VIP was found to double the mean lesion area when compared with that induced by ethanol alone (P < 0.05), an effect that was prevented by VIP antagonist (1 mumol/liter/100 g). A substance P antagonist (1 mumol/liter/100 g) also reduced the extent of gastric damage induced by coadministration of VIP and ethanol. VIP antagonist or substance P antagonist significantly reduced ethanol-induced gastric mucosal damage. Gastric mucosal levels of LTB4, LTC4, VIP, and substance P were significantly increased in ethanol-treated rats as compared with saline-treated animals (P < 0.05). The augmentation of ethanol-induced damage by VIP was associated with increased gastric mucosal levels of LTB4. In VIP-treated rats, gastric mucosal levels of substance P were found to be significantly increased compared with control rats (P < 0.05). Administration of VIP to pyloric-ligated rats significantly increased gastric acid output and blood pepsinogen A levels as compared with saline treated rats (P < 0.05). Ketotifen, a mast cell stabilizer (100 micrograms/100 g), administered orally 30 min before damage induction by ethanol, with or without VIP, totally abolished the damage of the surface epithelium of the entire gastric mucosa and significantly reduced the mucosal levels of LTC4 and LTB4 (P < 0.05). It is suggested that VIP is involved in the pathogenesis of acute ethanol-induced gastric mucosal damage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686841     DOI: 10.1007/bf01296069

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Neuropeptide regulation of the expression of immediate hypersensitivity.

Authors:  E J Goetzl; T Chernov; F Renold; D G Payan
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

2.  Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells.

Authors:  M A Lowman; R C Benyon; M K Church
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

3.  Effects of synthetic vasoactive intestinal peptide (VIP), secretin and their partial sequences on gastric secretion.

Authors:  G M Makhlouf; A M Zfass; S I Said; M Schebalin
Journal:  Proc Soc Exp Biol Med       Date:  1978-04

4.  Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon.

Authors:  S I Said; V Mutt
Journal:  Eur J Biochem       Date:  1972-07-13

5.  Mast cell heterogeneity: effects of neuroenteric peptides on histamine release.

Authors:  F Shanahan; J A Denburg; J Fox; J Bienenstock; D Befus
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

6.  The effect of vasoactive intestinal polypeptide on gastric acid secretion is predominantly mediated by somatostatin.

Authors:  M L Schubert
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

7.  Effect of vasoactive intestinal peptide on gastric secretion in the cat.

Authors:  M Vagne; S J Konturek; J A Chayvialle
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

8.  Vasoactive intestinal polypeptide is more potent than prostaglandin E2 as a vasodilator and oedema potentiator in rabbit skin.

Authors:  T J Williams
Journal:  Br J Pharmacol       Date:  1982-11       Impact factor: 8.739

9.  Gastroduodenal mucosal hormone content in duodenal ulcer disease.

Authors:  S Domschke; S R Bloom; T E Adrian; G Lux; M G Bryant; W Domschke
Journal:  Hepatogastroenterology       Date:  1985-08

10.  Modulatory effect of glucose on VIP-induced gastric somatostatin release.

Authors:  R Schmid; V Schusdziarra; M Classen
Journal:  Am J Physiol       Date:  1988-06
View more
  1 in total

1.  Sulphydryl blocker induced small intestinal inflammation in rats: a new model mimicking Crohn's disease.

Authors:  D Rachmilewitz; E Okon; F Karmeli
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.